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Cancer is one of the leading health concerns for human and animal health. Since
the tumorigenesis process is not completely understood and it is known that some
viruses can induce carcinogenesis, it is highly important to identify novel oncoviruses
and extensively study underlying oncogenic mechanisms. Here, we investigated a case
of diffuse histiocytic sarcoma in a 22 year old slow loris (Nycticebus coucang), using a
broad spectrum virus discovery technique. A novel parvovirus was discovered and the
phylogenetic analysis performed on its fully sequenced genome demonstrated that it
represents the first member of a novel genus. The possible causative correlation between
this virus and the malignancy was further investigated and 20 serum and 61 organ samples
from 25 animals (N. coucang and N. pygmaeus) were screened for the novel virus but
only samples collected from the originally infected animal were positive. The virus was
present in all tested organs (intestine, liver, spleen, kidneys, and lungs) and in all banked
serum samples collected up to 8 years before death. All attempts to identify a latent viral
form (integrated or episomal) were unsuccessful and the increase of variation in the viral
sequences during the years was consistent with absence of latency. Since it is well known
that parvoviruses are dependent on cell division to successfully replicate, we hypothesized
that the virus could have benefitted from the constantly dividing cancer cells and may not
have been the cause of the histiocytic sarcoma. It is also possible to conjecture that the
virus had a role in delaying the tumor progression and this report might bring new exciting
opportunities in recognizing viruses to be used in cancer virotherapy.
Keywords: parvovirus, virus discovery, slow loris, Nycticebus coucang, histiocytic sarcoma, VIDISCA,
hematopoietic tumor, oncovirus
INTRODUCTION
The Sunda slow loris (Nycticebus coucang), a Strepsirrhine pri-
mate which belongs to the family Lorisidae, is a nocturnal, arbo-
real prosimian species native to Indonesia (Sumatra), western
Malaysia (PeninsularMalaysia), Singapore and southern Thailand
(Nekaris and Streicher, 2008). Slow loris, listed as a vulnerable
species by the International Union for Conservation and Nature
(IUCN) (IUCNRed List of Threatened Species, available at: www.
iucnredlist.org), are protected by law in Malaysia, Thailand, and
Indonesia since their conservation status is a matter of concern.
The biggest threat endangering those animals is the pet trade—
they are the most commonly protected primates species sold as
exotic pets in southeast Asia (Nekaris and Nijman, 2007), but
habitat loss and the fact they are killed as crop pests also jeop-
ardize their survival (Nekaris and Streicher, 2008). Because of
these reasons a better understanding of the causes and the dynam-
ics of diseases in N. coucang is advantageous for conservation
attempts and captive management of this species (Remick et al.,
2009). In addition, valuable information can be gathered by the
study of diseases in non-human primates, which in turn might be
beneficial for human health.
We investigated a case of histiocytic sarcoma (HS) in a N. cou-
cang identified at the Duke Lemur Center (DLC) in Durham,
North Carolina. HS is a highly aggressive hematopoietic tumor
defined as a malignant proliferation of cells showing morpholog-
ical and immunophenotypic features of mature tissue histiocytes,
cells of the innate immune system derived from bone marrow
monocytes which differentiate into dendritic cells and tissue
localized macrophages (Fulmer and Mauldin, 2007; Takahashi
and Nakamura, 2013). Tumors can be localized or disseminated
with lymph nodes being the most common site of proliferation,
followed by organs of the gastrointestinal tract, spleen, soft tis-
sues, and skin (Takahashi and Nakamura, 2013). It is a rare type
of cancer in humans and cases have been reported in other species
of animals, including chickens, dogs, cats, camels, macaques, and
lemurs (Fulmer and Mauldin, 2007; Friedrichs and Young, 2008;
Soshin et al., 2008; Molenaar et al., 2009; Remick et al., 2009;
Takahashi and Nakamura, 2013). Although the cause of HS is
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largely unknown, a viral etiology can be postulated as the exis-
tence of viruses involved in the development of hematopoietic
cancers have been recognized, as in the case of Epstein Barr
and human T-lymphotropic virus-induced human lymphomas
and similar viruses in non-human primates (Miller et al., 1972;
Donahue et al., 1992; Feichtinger et al., 1992; Vereide and Sugden,
2009; Qayyum and Choi, 2014). Additionally it has been proven
that the subgroup J avian leukosis virus is associated with the
development of histiocytic sarcomatosis in chickens (Pandiri
et al., 2009) and an association between persistent Epstein Barr
virus infection and human HS has been reported (Kramer et al.,
1985). In this study we applied a sequence independent virus
discovery technique combined with high throughput sequenc-
ing, VIDISCA-454 (De Vries et al., 2011), to investigate the
possible involvement of a previously unknown virus in the devel-
opment of HS in a N. coucang. Several sequences with homol-
ogy to parvoviral genes were identified indicating the presence
of a novel parvovirus, whose genome was subsequently fully
sequenced.
Parvoviruses (viral family Parvoviridae) are small non-
enveloped single stranded DNA viruses which are able to infect
a wide range of species of vertebrates (subfamily Parvovirinae)
and arthropods (subfamily Densovirinae). According to the lat-
est ICTV classification (2013) 8 genera are recognized within the
subfamily Parvovirinae and 5 of them include viruses infecting
primates (Cotmore et al., 2013; Cotmore and Tattersall, 2014).
Some parvoviruses classified within the genusDependoparvovirus
need the presence of a helper virus for a productive infection
while viruses within other genera—the so called autonomous
parvoviruses—are S phase–dependent: cells must undergo the
S phase of growth for viral replication to occur (Berns,
1990).
The spectrum of parvovirus induced diseases, which mainly
involve young individuals, is very wide and varies from more
severe forms [like severe enteritis with high mortality in young
dogs (Goddard and Leisewitz, 2010), erythema infectiosum
or hydrops fetalis in children both caused by parvovirus B19
(Heegaard and Brown, 2002, p. 19), or the Aleutian disease in
minks (Best and Bloom, 2005)] to milder forms [like common
respiratory and gastrointestinal diseases in humans (Jartti et al.,
2012)]. Finally, parvovirus infections can also occur in asymp-
tomatic individuals (Heegaard and Brown, 2002, p. 19; Lau et al.,
2008; Clegg et al., 2012). Although there is no formal proof
of the existence of oncoviruses within this family, parvoviruses
have been reported in literature to be associated with both solid
and hematopoietic cancers (Fisgin et al., 2002; Li et al., 2012;
Schildgen et al., 2013; Ibrahem et al., 2014). However, since they
rely on actively replicating cells, the increased presence of these
viruses in individuals with cancer might also derive from the per-
missive nature of the tumor cells and some of these viruses have
even proven to possess oncosuppressive effects on transformed
cells (Berns, 1990; Nüesch et al., 2012).
Besides reporting the discovery and the molecular charac-
terization of a novel parvovirus, the scope of this study was
to determine whether a possible correlation existed between




The virus was identified in a 22 year old, male Nycticebus coucang
(slow loris) named Buddha, held in captivity for 22 years at the
Duke University Primate Center and which had no prior signif-
icant health issues. The individual was diagnosed with neoplasia
and euthanized due to poor condition, although a routine physi-
cal inspection 8 months before death revealed an enlarged spleen.
A complete postmortem examination was performed.
CLINICAL SAMPLES
Representative tissues of Buddha were collected and fixed in 10%
neutral formalin. Fixed tissue was processed routinely into paraf-
fin blocks and sections were stained with hematoxylin and eosin
and reviewed by a board of certified veterinary pathologist.
Twenty serum samples (belonging to 16 individuals: 11N. cou-
cang and 5 Nycticebus pygmaeus) and 61 organs collected at
necropsy (belonging to 17 individuals: 11 N. coucang—including
Buddha—and 6 N. pygmaeus) were screened for the presence of
the virus. Organ samples included 17 livers, 6 spleens, 15 kid-
neys, 10 lungs, 6 hearts, 7 intestines (5 small intestines and 2 large
intestines). Altogether these samples belonged to 25 individuals
(18 N. coucang and 7 N. pygmaeus) with various types of disease.
Liver, spleen, kidney, lung, and intestine samples from Buddha
were available as well as serum or whole blood collected on 4 dif-
ferent time points: year 2000 (serum), year 2005 (serum), year
2007 (whole blood), and year 2008 (serum).
Serum samples and organs were stored at−80◦C until virolog-
ical examinations were performed.
Housing management and sample collection from the ani-
mals in this report were approved by the appropriate federal and
institutional regulatory authorities.
VIRUS DISCOVERY
Sequence independent virus discovery was performed on a serum
sample collected from Buddha at necropsy (2008) with the previ-
ously described VIDISCA-454 procedure (De Vries et al., 2011)
with minor modifications. After a centrifugation and DNase
treatment to remove both intact cells and host DNA derived from
broken cells, viral nucleic acids were isolated from 100μl of serum
with the QIAmp DNA mini kit (Qiagen). Subsequent to the lig-
ation of adaptors containing specific Roche-454 primer binding
sequences, an amplicon size-selection was performed to prevent
the amplification of DNA fragments smaller than 200 bp using
Agencourt AMPure XP beads (Beckman Coulter), followed by 30
cycles of PCR amplification. The amplified library was subjected
to 2 consecutive purification rounds with Agencourt AMPure XP
beads to completely remove excess primers and short fragments
and DNA concentration was measured on a Qubit Fluorometer
(Quant-it ds DNA HS kit, Invitrogen). The library was pooled
with other samples, the average size of the whole library was
estimated with Agilent 2100Bioanalyzer (high sensitivity DNA
kit, Agilent Technologies) and the final concentration (copies/μl)
was calculated using the KAPA Library Quantification kit (KAPA
Biosystems). Samples were then diluted to a final concentration
of 1 million copies/μl and used as input for the emulsion PCR
(LIB-A emPCR kit, Roche) and 454 pyrosequencing (Roche).
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After sequencing, primer sequences were trimmed from every
read and sequences were assembled with CodonCode Aligner
software, version 3.5.6. The contigs (consensus sequences derived
from reads found multiple times) and unassembled sequences
were compared to known nucleotide and protein sequences in the
GenBank database using different standalone BLAST tools (blastn
and tblastx) (Altschul et al., 1990). Blast results were visualized
using the MEGAN software version 4.70.4 (Huson et al., 2011).
FULL GENOME SEQUENCING
Specific primers were designed on the viral sequences identi-
fied with VIDISCA-454 and PCRs using DreamTaq DNA poly-
merase (Thermo Scientific) were performed to connect frag-
ments. Sequencing reactions were carried out with nested primers
directly on the amplified products using the Big Dye termina-
tor chemistry (BigDye® Terminator v1.1 Cycle Sequencing Kit,
Applied Biosystems).
The ends of the genome were determined using genomic frag-
ments obtained by specific digestion with 2 different restriction
enzymes (MseI and CviAII from New England Biolabs) to obtain
overlapping fragments, to which VIDISCA adaptors were subse-
quently ligated; semi specific PCRs were then performed with a
combination of one primer annealing to the known viral sequence
and one to the adaptor. After sequencing the obtained ampli-
cons, the novel sequence was used as a template for new primer
design and the whole procedure was repeated until reaching the
end of the genome. Specific PCRs were used as confirmation.
All primers used for PCR and sequencing reactions are available
upon request.
VIRAL SCREENING AND DNA QUANTIFICATION
DNA isolations were performed from 100μl of serum with the
QIAmp DNAmini kit (Qiagen) and from 40μl of blood or about
20mg of tissue (about 5mg for spleen) with the DNeasy Blood
and Tissue kit (Qiagen). Absolute quantification of viral DNA
(copies/ml of serum or blood and copies/g of tissue) was achieved
using plasmid-based standards: a portion of the NS1 ORF (posi-
tion in the complete genome: nt 1129–1527) was amplified and
cloned into TOPO® cloning vector according to the instruc-
tions of the manufacturer (TOPO® TA cloning, Invitrogen),
followed by plasmid purification (Plasmid DNA purification
Nucleobond Xtra Midi, Macherey-Nagel) and quantification
(NanoDrop 2000c, Thermo Scientific). Quantitative Real Time
PCR assays were performed with IQ Supermix (BioRad) and
using 4μl of DNA as input, with the following primers
and probe: Buddha_RT_F, GCTAATCTGGTGGGAAGAAGG;
Buddha_RT_R, CCTTTGCGATCTACCCTGAC; Buddha_RT_P,
5′FAM—CCGCCAAGGAGAGCCTTAGCAC—TAMRA 3′. Real-
time PCR reactions were performed with the Light Cycler 480
system (Roche).
To detect possible differences between sequences obtained
from various organs or different years, all positive samples
were subjected to a specific amplification of a 1231 nt long
portion of the VP1 gene using DreamTaq DNA polymerase
(Thermo Scientific) with primers Buddha_VP_5F—ATGTCT
CCACTCATTCTGGTG—and Buddha_14_R—ACGATCTGG
GTAGATGACTTC. Amplicons were diluted 1:10 and directly
sequenced employing the Big Dye terminator chemistry (BigDye®
Terminator v1.1 Cycle Sequencing Kit, Applied Biosystems).
IDENTIFICATION OF INTEGRATED OR EPISOMAL VIRAL DNA
To detect the presence of latent viral forms (extra-chromosomal
circular episomal DNA or integrated DNA) in the different
tissues, specific PCR-based assays were designed. A graphical
overview of the methods used to detect latency is available in
Figure 1. For this purpose the DNA isolated from all organs col-
lected during the necropsy of Buddha (lung, liver, spleen, kidney,
small, and large intestine) and from blood (collected one year
before the animal died) were used as input.
To detect the presence of circularized viral genome an
inverted nested PCR was performed using primers annealing
at the end of the two open reading frames (ORFs) (Figure 1A):
I_Buddha_R1—CCTTGTTCGATCTGTCCAAAATAATTGC—
and I_Buddha_F1—CCAGTAGTGGAGAAGTCATCTACCC—
for the first step of amplification; I_Buddha_R2—GTAATTGCT
TTAATGGCTTTGATTCCCAG—and I-Buddha_F2—TGGAAG
TCGAGTAAAATACCGACACATG—for the nested amplifica-
tion. As a control DNA isolated from serum samples (collected in
2008 both with and without VIDISCA pre-treatment) was also
included.
To detect chromosome-integrated viral forms 3 different
approaches have been employed, of which 2 involved a spe-
cific enzymatic digestion of the isolated DNA (Figure 1B): 7.5μl
DNA eluate was cut (restriction site at nucleotides 868–873) in
a 20μl reaction mix containing 5 U of NdeI restriction enzyme
(New England Biolabs) during an incubation of 2 h at 37◦C.
Prior to inactivation, 5μl of cut DNA were collected and used
to perform a specific ligation of VIDISCA adaptors (De Vries
et al., 2011) to the digested fragments using 4 U of T4 DNA
ligase (life technologies). Afterwards 2 semi virus-specific nested
amplifications were performed using one primer complementary
to the virus (I_Buddha_R1 and I_Buddha_R2 for the 5 ′ side;
I_Buddha_F1 and I_Buddha_F2 for the 3 ′ side) and one adaptor
specific primer. In parallel, 5μl of the cut DNA was subjected to
an inactivation step for 20min at 65◦C, followed by an overnight
incubation at room temperature with 4 U of T4 DNA ligase to
allow self-ligation and consequent circularization of the digested
fragments (containing host sequences flanking the viral inte-
grated DNA). Two specific inverted nested PCRs were used after-
wards with primer pairs I_Buddha_F1/I_Buddha_R3 (TCCCGA
CACAAATAATCGGACAACC) and I_Buddha_R1/I_Buddha_F3
(GACGTGCTTTGTTAGAATCTGTTCCTG) during the first step
and I_Buddha_F2/I_Buddha_R4 (GAAATTTGAATTTCCATC
TTAGCTTGAGTC) and I_Buddha_R2/I_Buddha_F4 (CAAACC
CTGCAATGGTGTGTAGATG) during the second amplification
step.
The third approach for integrated DNA detection made use of
the Alu elements, DNA sequences which are highly repeated in
primate genomes (Häsler and Strub, 2006). A primer (Ny_Alu:
CCTCCCAGAGTGCTAGGATTGCAC) binding to one of these
region was designed (according to GenBank sequence with acces-
sion number DQ822059) and used alone (as a negative control)
or in combination with viral specific primers (I_Buddha_R1 or
I_Buddha_F1 for the first amplification step and I_Buddha_R2
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FIGURE 1 | Graphical overview of the methods used to detect latent
viral forms. (A) Method used to detect episomal genomic DNA. On the
top the genome organization of the Sl.L-PV-1, on the bottom a
representation of the predicted circular form. Red arrows represent primer
binding sites. The use of reverse primer annealing at the beginning of NS1
and forward primers annealing at the end of VP1 allows the amplification
the connecting genomic sequence. (B) Restriction enzyme based methods
to detect integrated virus. The purple lines represent the host genomic
sequence, the orange flashes indicate restriction enzyme sites and the
orange boxed indicate artificially ligated adaptors. (B1) It is shown how,
after overnight ligation of the digested DNA, the obtained fragment would
self-ligate in a circular form and how a specific amplification would allow
to amplify the integration site. (B2) It is shown how, after the ligation of
specific adaptors to the obtained digested fragments, a semi specific PCR
would allow the amplification of the integration site. (C) Method to detect
the integrated virus based on repeated Alu sequences in the host
genome. Purple boxes represent Alu sequences and red arrows represent
primer binding sites. A comparison of the PCR results obtained amplifying
the template with either a mixture of Alu binding primers and specific
primers or Alu binding primers alone (negative control) would allow to
amplify the integration site and determine which amplified fragment on gel
corresponds to it.
or I_Buddha_F2 for the nested amplification) to amplify the
putative integration region (Figure 1C).
All amplifications were performed by using 5μl of DNA as
input in a 50μl PCRmix containing DreamTaq DNA polymerase
(Thermo Scientific) and 0.2μM primers: PCRs were performed
according to the following thermo profile: initial denaturation
at 95◦C for 5min, followed by 35 cycles (25 during the nested
PCR) at 95◦C for 30 s, 60◦C for 30 s and 72◦C for 1.5min (for
the episomal DNA test) or 3min (for the integration tests) and
a final elongation cycle at 72◦C for 7min. Positive PCR prod-
ucts were cloned into the TOPO® cloning vector (TOPO® TA
cloning, Invitrogen) and sequenced employing Big Dye termina-
tor chemistry (BigDye® Terminator v1.1 Cycle Sequencing Kit,
Applied Biosystems) using betaine at a final concentration of 1M
to resolve secondary structures in the DNA.
SEQUENCE AND PHYLOGENETIC ANALYSIS
To characterize the phylogenetic placement of the novel virus, 38
NS1 amino acid sequences of known parvoviruses were down-
loaded from the GenBank database and aligned together with the
one predicted in this study from the obtained nucleotide sequence
using the Cobalt Multiple Alignment Tool (http://www.ncbi.nlm.
nih.gov/tools/cobalt/). Only complete sequences were included
in the analysis. Alignments were manually edited when needed
with BioEdit software version 7.0.5.3 (Hall, 1999) and then used
for phylogenetic inference. A model selection was performed to
identify the best model for distance estimation and phylogenetic
trees were constructed with Mega software version 6.06 (Tamura
et al., 2013) using the Maximum-likelihood method (Felsenstein,
1981). To test the robustness of the analysis a bootstrap analy-
sis (1000 replicates) (Felsenstein, 1985) was performed and only
clusters associated with a value higher than 75% were considered
significant.
To identify possible mutation between viral sequences ampli-
fied from different tissues or different time points, nucleotide
sequences were aligned using ClustalX version 2.1 (Larkin et al.,
2007) and identities between sequences were calculated with
BioEdit software version 7.0.9.0 (Hall, 1999).
DNA secondary structure predictions were obtained using
the mfold web server (http://mfold.rna.albany.edu/?q=mfold/
download-mfold).
ACCESSION NUMBERS
The genomic sequence obtained in this study has been deposited
in the GenBank database under the accession number KP120516.
RESULTS
We examine here the case of Buddha, a male slow loris, who was
euthanized at the age of 22 years because of diffuse HS. A serum
sample collected at necropsy was used as input for virus discovery
in search for a novel virus that could explain the disease.
PATHOLOGICAL DETAILS
During the postmortem examination the principal observations
included a significantly enlarged spleen with a homogeneous
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cut surface and a mottled liver with irregular patches of pallor.
Pancreatic and mediastinal lymph nodes were enlarged.
Incidental lesions included a cystic mass in the right mam-
mary gland and several small ulcers in the fundus of the stomach.
Histologic examination of the spleen revealed a loss of normal
architecture and an intense infiltration of neoplastic round to
polygonal cells with moderate variation in cell and nuclear sizes
(anisocytosis and anisokaryosis). Mitotic figures were common
and multinucleate cells were occasionally seen. In the liver there
were similar neoplastic cell aggregates surrounding the portal
veins and the central veins, expanding the associated connec-
tive tissue. Ingested red blood cells (erythrophagocytosis) by
neoplastic cells were also observed. Affected lymph nodes were
characterized by a loss of normal architecture which was replaced
by sheets of round to polygonal neoplastic cells similar to those
found in the liver and spleen. These findings led to a diagnosis of
disseminated histiocytic sarcoma.
Additional findings included evidence of an apocrine gland
cyst causing the mass in the right mammary gland. In addition
there was evidence of inflammation and necrosis in the adrenal
glands associated with a protozoal infection, interpreted to be
Toxoplasma gondii. In addition, large deeply basophilic intranu-
clear inclusions were found in a minority of adrenal cortical cells.
Renal tubules contained eosinophilic droplets in the epithelial
cells, as is often seen in mice with histiocytic sarcoma, although
the cause is not known. Chronic interstitial nephritis was also
evident.
IDENTIFICATION OF A NOVEL PARVOVIRUS AND COMPLETE GENOME
SEQUENCING
To explore the possibility of viral involvement in the etiopatho-
genesis of the HS we used VIDISCA-454, a sequence independent
virus identification technique which is able to detect virtually any
DNA and RNA virus from various clinical samples (van der Hoek
et al., 2004; Canuti et al., 2011; Jazaeri Farsani et al., 2013; Tan
et al., 2013; Canuti et al., 2014; OudeMunnink et al., 2014; Pariani
et al., 2014). A total of 8003 sequence reads were obtained from
the serum sample of the slow loris with HS and, among these,
5 sequences were identified with homology to different mem-
bers of the Parvovirinae subfamily: 3 were identified with blastn
(nucleotide identity: 62–70%) and 2 were only recognizable when
identity search was performed at amino acid level (amino acid
identity: 69–82%). Those recognized as viral fragments were used
as template for primer design, and a combination of specific PCRs
and genome walking techniques allowed retrieval of the almost
complete genomic sequence of the virus (only part of the termi-
nal repeats is lacking), which was tentatively named Slow Loris
parvovirus 1 (Sl.L-PV-1). The genomic sequence allowed us to
identify 3 further viral sequences which were not identifiable via
identity search. In total 35 reads (0.44% of the total) belonged to
the novel virus.
GENOME ORGANIZATION
The rules set by the parvovirus study group in the latest
ICTV report mention that a novel parvovirus, which lacked
isolation, can be classified within the Parvoviridae family only
if the complete coding sequence is provided and the typical
parvoviral motif patterns can be recognized (Cotmore et al.,
2013).
The genome of the novel parvovirus is 4844 nt and
the genomic organization reflects the other members of the
Parvovirinae subfamily with 2 large ORFs and terminal sequences
which form end loop structures important for viral replication,
although the structure of the loops could not be entirely resolved
since only partial sequences could be retrieved (Figure 2) (Berns,
1990). The first ORF—located at the 5′ part of the genome
(nt 146–1894)—putatively encodes for the non-structural pro-
tein NS1 (582 AA). The second ORF—located at the 3′ part (nt
2187–4655)—encodes for the capsid protein VP1 (822 AA).
Other molecular features typical of parvoviruses were also
identified (Figure 2). A phospholipase A2 domain of Sl.L-PV-1,
that is conserved in the majority of parvoviruses and which is
essential for viral genome transfer to the nucleus, is located at
the N-terminal part of the VP1 unique region and contains the
typical PLA2 catalytic domain (HDXXY, AA 140–144) and Ca++
binding loop (YXGXG, AA 117–121) (Zádori et al., 2001).
Another molecular marker of parvoviruses is the presence of
conserved helicase sequence motifs in the NS1 protein (Walker
et al., 1997; Lou et al., 2012). Within the carboxy-terminal half
of the NS1 protein of Sl.L-PV-1 (AA 336-423) the typical ATP
binding loop or p-loop (Walker box A: GXXXXGK(T/S)) could
be identified, immediately followed by the Mg++ binding Walker
B (hhhh(D/E)E) and B’ motifs. Finally, the C motif (a stretch of
hydrophobic residues usually followed by asparagine), common
to the helicases belonging to the superfamily type III, was also
present (Figure 2).
We were able to obtain only part of the sequences from the
terminal non coding regions, 148 and 192 nt of the 5′ and 3′
end respectively. An alignment of these 2 sequences shows that
they are 100% identical (but oriented in the opposite direction)
and start differentiating from the ATG start codon of NS1, which
becomes ACG on the 3′ side terminal sequence (Figure 3). These
data suggest that Sl.L-PV-1 possesses identical inverted terminal
repeats. Besides, a 44 nt sequence was identified which is present
only on the 3′ side of the genome, just after the TAA stop codon
of VP1/VP2, that contains a 21 nt region that can fold into a small
hairpin (Figures 2, 3).
PHYLOGENETIC ANALYSIS AND PROPOSED CLASSIFICATION
Phylogenetic analysis of Sl.L-PV-1 was performed using the pre-
dicted amino acid sequences of the NS1 protein belonging to
members of the Parvovirinae subfamily (Figure 4). In the phylo-
genetic tree the 8 Parvovirinae genera are indicated: each defined
cluster was supported by a significant bootstrap value (between
93 and 100). Only 2 viruses did not cluster in any of these 8
clades: a parvovirus identified in Artibeus jamaicensis fruit bat
(Aj-Bt-PV-1, which we previously reported as the first member
of a novel parvovirus genus, Canuti et al., 2011) and the Sl.L-PV-
1. Both viruses are located between the Dependoparvovirus and
the Tetraparvovirus genera and do not significantly cluster with
any other known parvovirus, possibly representing 2 independent
still undefined genera.
To better clarify the relationship between Sl.L-PV-1 and the
most closely related parvoviruses, the amino acid identities of
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FIGURE 2 | Genome organization of the slow loris parvovirus 1
(Sl.L-PV-1). Schematic representation of the genome organization of Sl.L-PV-1
with the two main ORF (NS1 and VP1) indicated with the respective
predicted protein size. On the top the helicase domain of Sl.L-PV-1 (AA
336–423) is compared with the one of other members of the Parvovirinae
sub-family. The conserved Walker motifs (A,B,B’,C) are indicated in boxes
(Walker et al., 1997; Lou et al., 2012). For sequences accession numbers see
Figure 3. The phospholipase A2 domain comparison between Sl.L-PV-1 (AA
109–167) and other members of the Parvovirinae sub-family is presented at
the bottom. The conserved Calcium binding domain (1) and enzymatic core
(2) motifs are indicated by boxes (Zádori et al., 2001). Finally, the hypothetical
5′ and 3′ specific terminal hairpins are represented by dashed lines and on
the right a small hairpin identified only on the 3′end of the genome is shown
just after the underlined VP1 stop codon. The mfold web server (http://mfold.
rna.albany.edu/?q=mfold/download-mfold) was used to predict the
secondary structure.
both NS1 and VP1 proteins within and between the clades
were calculated (Table 1). Considering NS1 protein, the virus
with the highest identity to Sl.L-PV-1 was the Bovine adeno-
associated virus (BAAV, 29.1%), followed by other members of
the Dependoparvovirus genus, which, on average, was the clade
closest to Sl.L-PV-1. The Tetraparvovirus clade and Aj-Bt-PV-1
are approximately equidistant from Sl.L-PV-1. The same trend
could be noted for Aj-Bt-PV-1.
The classification rules for parvoviruses state that a genus is
defined as a monophyletic group in which the NS1 amino acidic
sequences of all included viruses are generally more than 30%
identical to each other and less than 30% identical to those of
other genera (Cotmore et al., 2013). According to our analysis,
both Aj-Bt-PV-1 and Sl.L-PV-1 could be considered the first
members of 2 novel genera: their NS1 amino acid sequences
are less than 30% identical to the ones of the viruses in the
closest genera (Table 1), less than 25 and 27% respectively, and
they are not part of a bootstrap supported monophyletic group
(Figure 4).
SCREENING AND VIRUS QUANTIFICATION
Twenty serum and 61 organ samples altogether belonging to 25
individuals (18 N. coucang and 7 N. pygmaeus) were screened
for the presence of Sl.L-PV-1, but only samples collected from
the animal in which the virus was originally identified were pos-
itive. All organs collected during necropsy were positive for the
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FIGURE 3 | Alignment of the available inverted terminal repeat
sequences of Slow loris parvovirus 1 (Sl.L-PV-1). The 5′ side ITR is
oriented 5′ to 3′, while the 3′ side ITR is oriented in the opposite direction.
The start codon of NS1 as well as the stop codon of VP1 are highlighted in
gray. The sequence of the small hairpin unique to the 3′ side non-coding
region is underlined and in boldface.
virus, with high viral loads as shown in Table 2. Liver, spleen, and
kidneys were the organs where the virus reached the highest loads.
Surprisingly, all blood/serum samples collected at different
time points were PCR positive. Those samples were collected from
Buddha on a time frame of 8 years (from the year 2000 until 2008)
and the virus was constantly found at moderately high concen-
trations, with the highest titre found in whole blood (5.39E +
08 DNA copies/ml) 7 months prior to the death of the animal
(Table 2).
VIRUS EVOLUTION
A 1231 nt fragment of the VP1 ORF end was sequenced from
all positive samples in order to detect variation between differ-
ent body sites or among the 8 years of infection: 16 polymorphic
sites were noted (Table 3). The polymorphisms predominantly
included transitions (81.25%, 13/16) and only two were non-
synonymous. If we consider only the sequences obtained from
serum there is an accumulation of 5 substitutions (all transi-
tions located between codons 405 and 536) during the years,
one of which leads to an amino acid change. However, no fix-
ation can be accounted if we consider altogether the sequences
from 2008 (those retrieved both from serum and from all the
organs).
The appearance of new variable sites over time can also
be noted, like at codon position 645 where a polymorphism
appeared only in 2008. Interesting to notice is that kidneys and,
most of all, the intestine are the locations where most poly-
morphic sites characterizing earlier time points were conserved
(positions 742, 763, and 777).
LATENT VIRUS DETECTION
Since the virus was detected in samples collected from Buddha
during 8 years the presence of integrated or episomal viral
genomes could be postulated. Besides, the disruption of an
oncolytic gene caused by viral integration could have been at the
origin of the HS and therefore the presence of integrated viral
genomes in all tissues (including whole blood) was investigated
by means of three different methods - since the integration loca-
tion could not be predicted (Figure 1). No evidence for integrated
viruses could be found. In addition, there was also no evidence
of a circular covalently closed genomic form which could have
persisted in tissues as an episomal form.
DISCUSSION
Cancer is one of the leading cause of human death worldwide
and it represents a considerable health concern for domestic and
wild animals as well as animals kept in captivity (WHO|Cancer1 ;
Misdorp, 1996; Kelsey et al., 1998; McAloose and Newton, 2009;
Remick et al., 2009). Although the full process of tumorigene-
sis is not completely understood, it is known that accumulation
of mutations in proto-oncogenes (such as those involved in the
regulation or suppression of cell replication or tumors) or the
effect of viral infections are involved in the progression (Bergers
and Benjamin, 2003; McAloose and Newton, 2009). The number
of recognized oncogenic viruses is increasing and nowadays sev-
eral examples—both from the human and animal fields—are well
characterized. The best known examples are the papillomaviruses
causing cervical cancers in humans and different types of genital
and cutaneous cancers in aquatic mammals, the hepadnaviruses
causing hepatocellular carcinomas in humans and woodchucks,
the Epstein Barr virus which is responsible for Burkitt’s lym-
phoma or retroviruses which are at the origin of different types
of malignancies in humans and other mammals (McAloose and
Newton, 2009; Braoudaki and Tzortzatou-Stathopoulou, 2011;
Butt and Miggin, 2012; Pannone et al., 2014). It is therefore very
important to identify novel oncoviruses and extensively study
them in order to understand their tumorigenic mechanisms,
especially in light of future developments such as prevention
strategies.
In this study we investigated a case of diffuse histiocytic
sarcoma—a rare but very aggressive type of hematopoietic
tumor which can develop in different animal species (Fulmer
and Mauldin, 2007; Friedrichs and Young, 2008; Soshin et al.,
2008; Molenaar et al., 2009; Remick et al., 2009; Takahashi and
Nakamura, 2013). To investigate the possible viral involvement
in the etiopathogenesis of the HS a broad spectrum virus discov-
ery technique was employed, which is able to detect virtually any
DNA or RNA viruses present in a clinical sample (De Vries et al.,
2011, 2012; Oude Munnink et al., 2014). A novel parvovirus was
identified and molecularly fully characterized. The virus, which
we named Slow Loris parvovirus 1 (Sl.L-PV-1), is around 5 kb
1http://www.who.int/mediacentre/factsheets/fs297/en/ [Accessed May 19,
2014].
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FIGURE 4 | Phylogenetic analyses of slow loris parvovirus 1 (Sl.L-PV-1).
The evolutionary history of Sl.L-PV-1 and the other members of the
Parvovirinae subfamily was inferred using the Maximum Likelihood method
(Felsenstein, 1981) based on the rtREV + Freq model (Dimmic et al.,
2002), identified as the best fitting model after the model test analysis,
using MEGA6 (Tamura et al., 2013). A distance Gamma distribution was
used to model evolutionary rate differences among sites (+G, parameter =
2.5202). The rate variation model allowed for some sites to be
evolutionarily invariable ([+I], 4.0614% sites). All positions with less than
95% site coverage were eliminated. The outcome of the bootstrap
analysis (Felsenstein, 1985) is shown next to the branches. The genera are
designated by square brackets and the accession numbers of the
reference strains are indicated next to the strain name. The virus described
in this study is indicated in bold.
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Table 1 | Identities between and within the clades more closely related to Sl.L-PV-1.
Dependoparvovirus Tetraparvovirus Aj-Bt_PV-1 Sl.L-PV-1
Dependoparvovirus 81.87 (61–45) 17.21 (18.9–15.1) 21.01 (22.4–19.4) 23.4 (24.1–22.4)
43.27 (64.3–28)
Tetraparvovirus 50.14 (72.9–27.3) 18.8 (19.6–18.2) 20.4 (20.9–19.6)
21.18 (23.4–18.6) 46.45 (75.7–29.6)
Aj-Bt_PV-1 id 21.3
24.81 (26–22.4) 22.6 (23.1–22) id
Sl.L-PV-1 id
26.6 (29.1–24.5) 22.8 (25–19.9) 23.6 id
Values represent average percentage identity (upper limit—lower limit) calculated using representative members of each species in the clades. Values in bold
(bottom left) refers to NS1 amino acid sequence, while the other numbers (top right) refer to VP1 amino acid sequence. On the diagonal in italic are the identities
within each clade; id, identical. The extended analysis is available in the Supplementary Tables 1, 2.
Table 2 | Sl.L-PV-1 loads determined in different organs (collected at
necropsy in 2008) and from serum/blood samples collected during
various years.
Material Collection date Viral load (copies/g or
(mm/dd/yyyy) copies/ml)
Lung 06/03/2008 6.09E + 07
Small intestine 06/03/2008 4.82E + 07
Large intestine 06/03/2008 1.24E + 07
Liver 06/03/2008 1.87E + 08
Spleen 06/03/2008 1.79E + 08
Kidney 06/03/2008 1.43E + 09
Serum 03/21/2000 1.90E + 07
Serum 12/08/2005 4.20E + 07
Whole blood 11/08/2007 5.39E + 08
Serum* 06/03/2008 1.08E + 06
*After VIDISCA pre-treatment (centrifugation and DNase treatment prior to DNA
isolation)
in size and possesses all the molecular features typical of par-
voviruses, including sequences coding for conserved enzymatic
motifs and the 2 main ORFs, flanked by non-coding termi-
nal regions, which appear identical but inverted like described
for other parvoviruses (Lusby et al., 1980; Berns, 1990; Deiss
et al., 1990). The virus is phylogenetically located between the
Dependoparvovirus and the Tetraparvovirus genera and, accord-
ing to the classification rules defined by the ICTV (Cotmore et al.,
2013), is possibly the first member of a new genus.
Thanks to the availability of a series of serum and organ sam-
ples collected over multiple years from slow loris with various
diseases, we were able to screen different samples from a total of
25 individuals belonging to theN. coucang species and to the clos-
est related species N. pygmaeus. No other animal was positive for
the virus but, as expected, all organs collected during the necropsy
were positive, as also reported for other parvoviruses (Meunier
et al., 1985; Canuti et al., 2011), and liver, spleen and kidneys
were the organs where the virus reached the highest loads. The
high viral concentrations found in these organs might reflect their
elevated content of blood and blood cells. Besides, during the his-
tological investigation the presence of basophilic inclusions in the
renal tissue could be observed and these might represent parvovi-
ral accumulations, similar to other reports for parvoviruses both
in vivo (Hayes et al., 1979; Bestetti and Zwahlen, 1985; Porter
et al., 1988; Decaro and Buonavoglia, 2012) and in vitro (Inaba
et al., 1973; Oleksiewicz et al., 1996). Surprisingly, all blood or
serum samples collected during various years were positive at a
rather constant load: we could detect viremia 8 years prior to the
death of the animal. Given the involvement in the disease of white
blood cells, a presumed condition of immunosuppression (caused
either by the virus, the tumor, or by a combination of these 2
factors) can be postulated and might be a possible explanation
for the fact that the virus was not cleared in 8 years. The sup-
posed presence of immunodeficiency in the loris is supported by
the detection of opportunistic infections, as the pathological tests
reported the presence of Toxoplasma gondii infection.
Since HS is a fast and very aggressive type of cancer we
could have hypothesized that the virus was present in the Loris
before tumor development. Histiocytes can refer to cells of
either the macrophage or dendritic cell lineage as both arise
from a common precursor cell. Neoplasms of histiocytes can
arise from macrophages or one of two types of dendritic cells,
Langerhans cells or interstitial dendritic cells. Langerhans cells
are found within the epithelium and interstitial dendritic cells
occupy a perivascular position in most tissues. Most forms of
HS in animals arise as a malignant proliferation of interstitial
dendritic cells, although there is one form, the hemophagocytic
variant, that arises from macrophages (Fulmer and Mauldin,
2007; Takahashi and Nakamura, 2013; Moore, 2014). There is
no established classification scheme for HS in prosimians. We
interpreted this tumor to have most likely arisen from intersti-
tial dendritic cells. Some parvoviruses have proven tropism for
cells of the hematopoietic system and the bone marrow pro-
viding the perfect condition for parvoviral replication, since a
wide spectrum of cells at different dividing stages are present
and parvoviruses need actively dividing cells (S phase) to repli-
cate (Berns, 1990; Segovia et al., 1991). In fact, hematopoietic
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Table 3 | Nucleotide polymorphisms in Sl.L-PV-1 identified over time and in different organs.
nt 3399 3443 3506 3530 3722 3746 3794 3923
AA 405 (V) 419 (L) 440 (Y) 448 (E) 512 (P) 520 (Q) 536 (E) 579 (T)
Serum 2000 A (I) T T G T A A Y
Serum 2005 R (V/I) Y Y R Y R R Y
Whole blood 2007 R (V/I) Y Y R Y R R Y
Serum 2008 G C C G C R G C
Small intestine R (V/I) Y Y G Y A R C
Large intestine G Y Y G Y R R C
Lung G C C G C A G C
Spleen G C C G Y A G C
Liver G C C G Y A G C
Kidneys R (IV/I) Y Y R Y R R Y
nt 3992 4040 4121 4331 4412 4475 4517 4558
AA 603 (S) 618 (R) 645 (F) 715 (G) 742 (S) 763 (T) 777 (V) 791 (S)
Serum 2000 Y R T T R M Y G
Serum 2005 Y R T K A C Y K (S/I)
Whole blood 2007 Y R T K A C C K (S/I)
Serum 2008 C R Y K A C C K (S/I)
Small intestine C R Y K R M Y K (S/I)
Large intestine Y R Y K A C C K (I/S)
Lung C A Y K A C C K (I/S)
Spleen Y R Y K A C C K (I/S)
Liver C A Y K A C C K (I/S)
kidneys Y A Y K A C C K (I/S)
Nucleotide positions refer to the whole genome as reported in GenBank (AN: KP120516); amino acids positions refer to the VP1 ORF. Where the mutation caused
an amino acid change the new amino acid is indicated. Polymorphisms are indicated: Y (C or T), R (A or G), K (T or G),M (C or A).
disorders, like leucopenia or alterations in the bone marrow, can
be observed in infected individuals (Larsen et al., 1976; Boosinger
et al., 1982).
Although there is no formal proof of the existence of onco-
parvoviruses, a causative link between the novel parvovirus and
the HS could not be ruled out and therefore we investigated this
hypothesis by exploring the eventual presence of latent forms of
the virus. It is known that parvoviruses can establish latency by
integrating in their hosts’ genome (Schnepp et al., 2005; Kapoor
et al., 2010), and an integration event might cause the disruption
of important onco-suppressors and be one of the initial causes
for tumor development. Episomal DNA forms of various par-
voviruses have recently been detected (Kapoor et al., 2011; Zhao
et al., 2012) and parvoviral DNA was found to persist in differ-
ent tissues (Schneider et al., 2008; Norja et al., 2012), sometimes
even in correlation with tumors (Li et al., 2012; Schildgen et al.,
2013), although without a causative link. Since it was impossi-
ble to predict in which way the virus would have persisted, this
hypothesis was tested with 4 different methods aiming at identify-
ing either potentially integrated viral DNA or circular covalently
closed genome persisting in tissues as episomal forms. None of
these approaches gave evidence for latent forms of the virus in
any of the tested organs (including whole blood).
A mutation hotspot located on the end side of the VP1 ORF
was identified and an increase in variation during the years was
observed. The evolutionary rates estimated in literature for par-
voviruses are around 10E-4 substitutions per site per year in the
studied genomic region (Shackelton and Holmes, 2006; Zehender
et al., 2010; Streck et al., 2011) and the amount of substitutions
we observed reflect those rates. However, these previously pub-
lished rates have been estimated at an animal population level
and not inter-host. In addition, fixation rates are connected to
the transmission route of the virus: the sequences of the viral sub-
population which are transmitted to other individuals depend on
the viral variation at the body site where the virus is shed. Since
no other infected individual has been identified no postulations
could be made on the transmission route of the virus and also
no evolutionary rate estimations were possible. Nevertheless, the
observed increase in sequence variation over time is inconsistent
with a latency hypothesis: an integrated virus would evolve at
the same evolutionary rate as its host and therefore, in case of
integration, no variation would be observed.
It is reasonable to believe that the Sl.L-PV-1 was not the cause
of the malignancy but merely found the ideal replication condi-
tion in cancer cells since, as discussed above, it is well known that
parvoviruses need actively replicating cells (S-phase) in order to
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proliferate (Berns, 1990). In fact it is known that certain viruses,
called oncolytic viruses, have tropism for specific cancer cells and
they can even lead to “spontaneous regression” of malignancies
(Butt andMiggin, 2012; Sze et al., 2013). This has been proven for
the adeno-associated dependoparvovirus, although in an indirect
way by enhancing adenoviral replication, and for a rodent par-
vovirus (Nüesch et al., 2012; Laborda et al., 2013). Future research
will have to clarify whether this viral infection precedes tumor
development and has a role in the oncogenic process, whether the
virus simply benefits from the replication activity of the cancer
cells or if the persistent viremia has no correlation with the HS.
An answer to this question will be obtained by identifying the cell
types where viral replication occurs after the detection of other
infected loris and the constant monitoring of their physical con-
dition and disease progression, and after the discovery of related
viruses in other animals with similar malignancies. Although
more studies are required to provide a conclusive answer, the
infection with Sl.L-PV-1 might have delayed tumor progression.
If this mechanismwill be proven feasible new exciting possibilities
might open for oncolytic parvovirotherapy (Nüesch et al., 2012;
Russell et al., 2012).
In conclusion we discovered and molecularly characterized a
novel parvovirus, the first member of a not yet defined genus
and the first described in prosimians. The virus was identified in
a slow loris with HS but we found no evidence for a causative
involvement in the neoplastic disease and postulated that the
virus had a replication advantage derived from the constantly
replicating cancer cells.
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